Cargando…

Small molecules to perform big roles: The search for Parkinson's and Huntington's disease therapeutics

Neurological motor disorders (NMDs) such as Parkinson's disease and Huntington's disease are characterized by the accumulation and aggregation of misfolded proteins that trigger cell death of specific neuronal populations in the central nervous system. Differential neuronal loss initiates...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pérez-Arancibia, Rodrigo, Cisternas-Olmedo, Marisol, Sepúlveda, Denisse, Troncoso-Escudero, Paulina, Vidal, Rene L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868863/ https://www.ncbi.nlm.nih.gov/pubmed/36699535 http://dx.doi.org/10.3389/fnins.2022.1084493

Ejemplares similares

On the Right Track to Treat Movement Disorders: Promising Therapeutic Approaches for Parkinson’s and Huntington’s Disease
por: Troncoso-Escudero, Paulina, et al.
Publicado: (2020)

Insulin-like growth factor 2 and autophagy gene expression alteration arise as potential biomarkers in Parkinson’s disease
por: Sepúlveda, Denisse, et al.
Publicado: (2022)

Contribution of Autophagy-Lysosomal Pathway in the Exosomal Secretion of Alpha-Synuclein and Its Impact in the Progression of Parkinson’s Disease
por: Sepúlveda, Denisse, et al.
Publicado: (2022)

Therapeutic potential of insulin-like growth factor 2 in Huntington’s disease: controlling proteostasis to alleviate the load of misfolded protein
por: Troncoso-Escudero, Paulina, et al.
Publicado: (2021)

Transcriptional and Histone Acetylation Changes Associated with CRE Elements Expose Key Factors Governing the Regulatory Circuit in the Early Stage of Huntington’s Disease Models
por: Arancibia-Opazo, Sandra, et al.
Publicado: (2023)

Outside in: Unraveling the Role of Neuroinflammation in the Progression of Parkinson's Disease
por: Troncoso-Escudero, Paulina, et al.
Publicado: (2018)

IGF2 prevents dopaminergic neuronal loss and decreases intracellular alpha-synuclein accumulation in Parkinson’s disease models
por: Arcos, Javiera, et al.
Publicado: (2023)

The Emerging Landscape of Natural Small-molecule Therapeutics for Huntington’s Disease
por: Bhat, Shahnawaz Ali, et al.
Publicado: (2023)

A phenolic-rich extract from Ugni molinae berries reduces abnormal protein aggregation in a cellular model of Huntington’s disease
por: Pérez-Arancibia, Rodrigo, et al.
Publicado: (2021)

Short G-rich oligonucleotides as a potential therapeutic for Huntington's Disease
por: Skogen, Michael, et al.
Publicado: (2006)

Pathogenic SREK1 decrease in Huntington’s disease lowers TAF1 mimicking X-linked dystonia parkinsonism
por: Hernández, Ivó H, et al.
Publicado: (2020)

Huntington’s Disease Presenting as Adult-Onset Parkinsonism
por: Kwak, In Hee, et al.
Publicado: (2022)

Mitochondrial Bioenergy in Neurodegenerative Disease: Huntington and Parkinson
por: Tassone, Annalisa, et al.
Publicado: (2023)

Therapeutic Strategies in Huntington's Disease
por: Kanazawa, Ichiro
Publicado: (2006)

Therapeutic Advances for Huntington’s Disease
por: Kumar, Ashok, et al.
Publicado: (2020)

Innovative Therapeutic Approaches for Huntington’s Disease: From Nucleic Acids to GPCR-Targeting Small Molecules
por: Komatsu, Hidetoshi
Publicado: (2021)

Molecule of the month: miRNA and Huntington's disease (HD)
por: Shapshak, Paul
Publicado: (2013)

Therapeutic Advances in the Management of Huntington’s Disease
por: Abdulrahman, Ganiy Opeyemi
Publicado: (2011)

In search of the big bang
por: Gribbin, John
Publicado: (1987)

In search of the Big Bang
Publicado: (2008)

CERN: Probing big molecules
Publicado: (1988)

Thinking big with small molecules
por: Mruk, Karen, et al.
Publicado: (2015)

Gait dynamics in mouse models of Parkinson's disease and Huntington's disease
por: Amende, Ivo, et al.
Publicado: (2005)

Therapeutic and Mechanistic Effects of Curcumin in Huntington’s Disease
por: Labanca, Fabiana, et al.
Publicado: (2021)

Structured Search for Big Data
por: Gilula, Mikhail
Publicado: (2015)

Huntington’s Disease: The Past, Present, and Future Search for Disease Modifiers
por: Clabough, Erin B.D.
Publicado: (2013)

Parkinsonism with a Hint of Huntington’s from 29 CAG Repeats in HTT
por: JOT, Sipilä
Publicado: (2019)

Serinol: small molecule - big impact
por: Andreeßen, Björn, et al.
Publicado: (2011)

Auxin: small molecule, big impact
por: Weijers, Dolf, et al.
Publicado: (2018)

Nanoantibodies: small molecules, big possibilities
por: Pedreáñez, Adriana, et al.
Publicado: (2021)

Therapeutic Approaches for Inhibition of Protein Aggregation in Huntington's Disease
por: Kim, Sangjune, et al.
Publicado: (2014)

Impaired Redox Signaling in Huntington’s Disease: Therapeutic Implications
por: Paul, Bindu D., et al.
Publicado: (2019)

Current and Possible Future Therapeutic Options for Huntington’s Disease
por: Ferguson, Mackenzie W., et al.
Publicado: (2022)

Searching for Answers: Information-Seeking by Young People At-Risk for Huntington’s Disease
por: Chase, Colby L., et al.
Publicado: (2022)

Modulation of the glutamatergic transmission by Dopamine: a focus on Parkinson, Huntington and Addiction diseases
por: Gardoni, Fabrizio, et al.
Publicado: (2015)

Mitochondrial Quality Control in Neurodegenerative Diseases: Focus on Parkinson's Disease and Huntington's Disease
por: Franco-Iborra, Sandra, et al.
Publicado: (2018)

Cerebrospinal fluid levels of proenkephalin and prodynorphin are differentially altered in Huntington’s and Parkinson’s disease
por: Barschke, Peggy, et al.
Publicado: (2022)

Atypical parkinsonism can be a presenting feature of late‐onset Huntington's disease
por: Salari, Mehri, et al.
Publicado: (2022)

Community search over big graphs
por: Huang, Xin, et al.
Publicado: (2019)

Connectivity mapping uncovers small molecules that modulate neurodegeneration in Huntington’s disease models
por: Smalley, Joshua L., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ktkf3ik8ug8tl0l9ai4p2u25fo